Vogels Chantal B F, Breban Mallery I, Alpert Tara, Petrone Mary E, Watkins Anne E, Ott Isabel M, de Jesus Jaqueline Goes, Claro Ingra Morales, Ferreira Giulia Magalhães, Crispim Myuki A E, Singh Lavanya, Tegally Houriiyah, Anyaneji Ugochukwu J, Hodcroft Emma B, Mason Christopher E, Khullar Gaurav, Metti Jessica, Dudley Joel T, MacKay Matthew J, Nash Megan, Wang Jianhui, Liu Chen, Hui Pei, Murphy Steven, Neal Caleb, Laszlo Eva, Landry Marie L, Muyombwe Anthony, Downing Randy, Razeq Jafar, de Oliveira Tulio, Faria Nuno R, Sabino Ester C, Neher Richard A, Fauver Joseph R, Grubaugh Nathan D
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP 05403-000, Brazil.
medRxiv. 2021 Mar 12:2021.01.28.21250486. doi: 10.1101/2021.01.28.21250486.
With the emergence of SARS-CoV-2 variants that may increase transmissibility and/or cause escape from immune responses , there is an urgent need for the targeted surveillance of circulating lineages. It was found that the B.1.1.7 (also 501Y.V1) variant first detected in the UK could be serendipitously detected by the ThermoFisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike Δ69-70, would cause a "spike gene target failure" (SGTF) result. However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern that lack spike Δ69-70, such as B.1.351 (also 501Y.V2) detected in South Africa and P.1 (also 501Y.V3) recently detected in Brazil . We identified a deletion in the ORF1a gene (ORF1a Δ3675-3677) in all three variants, which has not yet been widely detected in other SARS-CoV-2 lineages. Using ORF1a Δ3675-3677 as the primary target and spike Δ69-70 to differentiate, we designed and validated an open source PCR assay to detect SARS-CoV-2 variants of concern . Our assay can be rapidly deployed in laboratories around the world to enhance surveillance for the local emergence spread of B.1.1.7, B.1.351, and P.1.
随着可能增加传播性和/或导致免疫逃逸的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的出现,迫切需要对流行谱系进行针对性监测。研究发现,在英国首次检测到的B.1.1.7(也称为501Y.V1)变体可通过赛默飞世尔科技公司的TaqPath COVID-19聚合酶链反应(PCR)检测意外发现,因为这些病毒中的一个关键缺失,刺突蛋白Δ69-70,会导致“刺突基因靶点失败”(SGTF)结果。然而,SGTF结果对B.1.1.7并不具有决定性,并且该检测方法无法检测到缺乏刺突蛋白Δ69-70的其他关注变体,例如在南非检测到的B.1.351(也称为501Y.V2)和最近在巴西检测到的P.1(也称为501Y.V3)。我们在所有这三种变体中鉴定出开放阅读框1a(ORF1a)基因中的一个缺失(ORF1a Δ3675-3677),该缺失在其他SARS-CoV-2谱系中尚未被广泛检测到。以ORF1a Δ3675-3677作为主要靶点并结合刺突蛋白Δ69-70进行区分,我们设计并验证了一种开源PCR检测方法来检测SARS-CoV-2关注变体。我们的检测方法可在世界各地的实验室中快速部署,以加强对B.1.1.7、B.1.351和P.1在当地出现和传播的监测。